Furthermore, patients are currently being recruited for a phase 1 trial to test the safety and efficiency of G3 CD19 CAR-T cells containing 4-1BB and CD28 co-stimulatory domains in adults with relapsed or refractory CD19-positive B acute lymphoblastic leukemia [12]. Here, CD19 is linked to acute lymphoblastic leukemia.